Cart
sales@molnova.com
Crenolanib
CAS No. 670220-88-9
Crenolanib ( CP-868596;CP 868596;CP868596 )
Catalog No. M15561 CAS No. 670220-88-9
Crenolanib (CP-868596) is a potent, selective PDGFR/Flt-3 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 48 | In Stock |
|
| 5MG | 74 | In Stock |
|
| 10MG | 119 | In Stock |
|
| 25MG | 177 | In Stock |
|
| 50MG | 255 | In Stock |
|
| 100MG | 420 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCrenolanib
-
NoteResearch use only, not for human use.
-
Brief DescriptionCrenolanib (CP-868596) is a potent, selective PDGFR/Flt-3 inhibitor.
-
DescriptionCrenolanib (CP-868596) is a potent, selective PDGFR/Flt-3 inhibitor with Ki of 3.2, 2.1 and 0.74 nM for wild-type PDGFRα, PDGFRβ and FLT3, respectively; displays >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src; also is a potent inhibitor of PDGFRα D842V-mutant kinase with IC50 of 10 nM, significantly more potent than imatinib in inhibiting the kinase activity of imatinib-resistant PDGFRA kinases (D842I, D842V, D842Y, DI842-843IM, and deletion I843); Crenolanib is active against models of drug-resistant FLT3-ITD-positive AML.Blood Cancer Phase 3 Clinical
-
SynonymsCP-868596;CP 868596;CP868596
-
PathwayTyrosine Kinase
-
TargetFLT3
-
RecptorPDGFRα;PDGFRβ;FLT3
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number670220-88-9
-
Formula Weight443.54
-
Molecular FormulaC26H29N5O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESNC1CCN(C2=C3N=C(N4C=NC5=CC(OCC6(C)COC6)=CC=C45)C=CC3=CC=C2)CC1
-
Chemical Name4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Heinrich MC, et al. Clin Cancer Res. 2012 Aug 15;18(16):4375-84.
2. Zimmerman EI, et al. Blood. 2013 Nov 21;122(22):3607-15.
3. Galanis A, et al. Blood. 2014 Jan 2;123(1):94-100.
4. Smith CC, et al. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24.
2. Zimmerman EI, et al. Blood. 2013 Nov 21;122(22):3607-15.
3. Galanis A, et al. Blood. 2014 Jan 2;123(1):94-100.
4. Smith CC, et al. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24.
molnova catalog
related products
-
KIN1148
KIN1148 is a novel small-molecule adjuvant that acts through the RIG-I pathway and IRF-3 transcription factor to stimulate inN/Ate immunity and protection following viral infection.
-
Quizartinib
Quizartinib (AC220) is a potent, selective, second-generation FLT3 inhibitor with Kd of 1.6 nM.
-
Quizartinib hydrochl...
Quizartinib (AC220) is a potent, selective, second-generation FLT3 inhibitor with Kd of 1.6 nM.
